Ontology highlight
ABSTRACT:
SUBMITTER: Allert C
PROVIDER: S-EPMC9522596 | biostudies-literature | 2022 Oct
REPOSITORIES: biostudies-literature
Allert Catana C Waclawiczek Alexander A Zimmermann Sarah Miriam Naomi SMN Göllner Stefanie S Heid Daniel D Janssen Maike M Renders Simon S Rohde Christian C Bauer Marcus M Bruckmann Margarita M Zinz Rafael R Pauli Cornelius C Besenbeck Birgit B Wickenhauser Claudia C Trumpp Andreas A Krijgsveld Jeroen J Müller-Tidow Carsten C Blank Maximilian Felix MF
Leukemia 20220902 10
FLT3 tyrosine kinase inhibitor (TKI) therapy evolved into a standard therapy in FLT3-mutated AML. TKI resistance, however, develops frequently with poor outcomes. We analyzed acquired TKI resistance in AML cell lines by multilayered proteome analyses. Leupaxin (LPXN), a regulator of cell migration and adhesion, was induced during early resistance development, alongside the tyrosine kinase PTK2B which phosphorylated LPXN. Resistant cells differed in cell adhesion and migration, indicating altered ...[more]